Back to News
Market Impact: 0.2
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP reminded investors of a shareholder class-action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The notice represents a legal and reputational risk for Capricor, though the excerpt provides no allegations, damages, class period, or operational impact details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
CAPR-0.85
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- ‘Imposed significant financial harm’: 20 states join the FTC in suing Dollar General for ‘deceptive pricing practices’ despite ‘corporate knowledge’
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Anthropic’s dual-class share structure borrows ideas from Mark Zuckerberg, Elon Musk—and the New York Times
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- Genmab shares jump 13% on colorectal cancer drug trial results
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Use AI for an Initiating Coverage Report
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)